



Press Release

GRAFTYS AND ITS PARTNER LAS BRASIL CROSS THE MILESTONE OF 10,000 GRAFTYS® HBS UNITS SOLD IN BRAZIL

Jumet (Belgium), December 01, 2020 – GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, is proud to announce that as a fruitful result of 10 years’ partnership with its distributor - LAS Brasil, the milestone of 10,000 units of GRAFTYS® HBS sold in Brazil has been crossed during the third quarter of 2020.

GRAFTYS® HBS is a calcium phosphate bone graft substitute, which offers very low viscosity to facilitate remote injections into closed bone cavities. GRAFTYS® HBS is a macroporous resorbable self-hardening cement with unparalleled injectability and ergonomics thanks to its unique chemical composition and all-in-one closed double-compartment preparation and injection system. Despite such a high injectability and contrarily to other injectable cements, GRAFTYS® HBS displays a mechanical resistance similar to that of trabecular bone while being fast resorbed and replaced by new quality bone.

Enrico Bastianelli, Chief Executive Officer of Graftys, said: “We’d like to thank LAS Brasil’s team for this incredible achievement and their outstanding contribution over the past 10 years. Such long-term partnerships associated with strong sales records prove our commitment to continuously search for the best solution for the surgeons’ and patients’ medical needs. We are looking forward to the next 10 years’ collaboration!”

João Bianchi, Chief Operating Officer at LAS Brasil commented: “The marks of 10 years of partnership and 10,000 units sold of Graftys HBS are a significant milestone achievement and proof of a safe and effective product. LAS Brasil is looking forward to the next 10 years of partnership to continue offering Brazilian patients and doctors a cutting-edge product like Graftys® HBS.”

Contact: Enrico Bastianelli at news@graftys.com

For background information: www.graftys.com

About Graftys

Graftys is an innovation-driven medtech company committed to the development and manufacturing of synthetic bone biomaterials. Graftys’ products are registered in more than 30 countries worldwide, including Europe, the USA, Canada, Australia, and South America. Graftys’ mission is to become a major player in the design, manufacturing & distribution of bone biomaterials, thanks to a solid portfolio of products built on clinical evidence and addressing patient’s/surgeon’s medical needs, and thanks to an innovation-driven pipeline through partnerships with leading academic research institutions in Europe.